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Summary {#efs25908-sec-0001}
=======

Chlorpyrifos‐methyl is an active substance covered by the third batch of the renewal programme for pesticides ('AIR3') in accordance with Commission Implementing Regulation (EU) No 844/2012.

Applications (June 2013) and supplementary dossiers (July 2015) for the renewal of approval of the active substance chlorpyrifos‐methyl were submitted by Dow AgroSciences and by Sapec Agro SA (currently Ascenza Agro S.A.).

An initial evaluation of the dossiers was provided by the rapporteur Member State (RMS) Spain in the Renewal Assessment Report (RAR) which was submitted to the European Food Safety Authority (EFSA) in July 2017. Subsequently, EFSA initiated a peer review of the pesticides risk assessment on the RMS evaluation in line with the provisions of Commission Implementing Regulation (EU) No 844/2012.

The commenting period was completed and included a public consultation on the RAR. Following evaluation of the comments received as well as the additional information provided by the applicants in response to a request in accordance with Article 13(3) of Regulation (EU) No 844/2012, a meeting of experts from EFSA and Member States, including relevant experts from the EFSA Panel on Plant Protection Products and their Residues (PPR Panel), took place in April 2019 to discuss certain elements related to mammalian toxicology.

After the Pesticides Peer Review Experts' meeting in April 2019, EFSA reconsidered the read‐across approach applied for the hazard identification of chlorpyrifos‐methyl after a full comparison of the available toxicological data: it was agreed to rediscuss this issue in an additional 'ad hoc' experts' meeting since EFSA considered that the outcome of the discussions might had an impact on the assessment of specific studies, on the possibility to consider if criteria for classification may be met, as well as on the setting of reference values for chlorpyrifos‐methyl. EFSA therefore organised an expert meeting, which took place on 5 September 2019.

On 31 July 2019, upon mandate of the European Commission, EFSA delivered a statement containing a summary of the main outcome of the assessment related to mammalian toxicology and human health following the Pesticides Peer Review Expert discussions in mammalian toxicology held between 1 and 5 April 2019, where the approach taken by the experts for chlorpyrifos‐methyl was largely based on its structural similarity with chlorpyrifos. In addition, EFSA included considerations whether the active substance can be expected to meet the approval criteria which are applicable to human health as laid down in Article 4 of Regulation (EC) No 1107/2009. During the experts' meeting held in September 2019, the majority of experts confirmed the conclusions reached at the April 2019 meeting.

The available regulatory genotoxicity data set submitted for chlorpyrifos‐methyl did not show any concern. The experts highlighted that very limited literature data were retrieved specifically for chlorpyrifos‐methyl. Considering also the read‐across discussion, most experts decided to precautionary apply to chlorpyrifos‐methyl the same conclusions as for chlorpyrifos. Therefore, the experts concluded that the genotoxicity potential of chlorpyrifos‐methyl remains as unclear as that of chlorpyrifos.

As for the developmental neurotoxicity (DNT), a DNT study was available, which did not show relevant effects, however, it had significant limitations related to the few controls available, making a reliable statistical analysis not possible. Therefore, all the experts, but one, agreed that, the DNT study on chlorpyrifos‐methyl being inconclusive, a specific DNT no observed adverse effect level (NOAEL) could not be set and the lowest observable adverse effect level (LOAEL) of 0.3 mg/kg body weight (bw) per day derived from the data on chlorpyrifos (study from 1998; Spain, [2019b](#efs25908-bib-0024){ref-type="ref"}) could be conservatively applied to chlorpyrifos‐methyl.

Based on the above, also in the case of chlorpyrifos‐methyl, the experts agreed that no reference values could be set, a fact that made it impossible to perform a risk assessment for consumers, operators, workers, bystanders and residents.

The experts conservatively applied the same approach as for chlorpyrifos, considering that chlorpyrifos‐methyl would also meet the criteria for classification as toxic for reproduction category 1B (regarding developmental toxicity). EFSA expresses some reservations on this approach since such a conservative approach may not apply to classification and labelling.

Based on the above, it is considered that the approval criteria which are applicable to human health as laid down in Article 4 of Regulation (EC) No 1107/2009 are not met.

1. Introduction {#efs25908-sec-0003}
===============

Chlorpyrifos‐methyl is an active substance covered by the third batch of the renewal programme for pesticides ('AIR3') in accordance with Commission Implementing Regulation (EU) No 844/2012[1](#efs25908-note-1005){ref-type="fn"}.

Applications (June 2013) and supplementary dossiers (July 2015) for the renewal of approval of the active substance chlorpyrifos‐methyl were submitted by Dow AgroSciences and by Sapec Agro SA (currently Ascenza Agro S.A.). The rapporteur Member State (RMS) is Spain and the co‐rapporteur Member State (co‐RMS) is Poland.

An initial evaluation of the dossiers was provided by the RMS in the Renewal Assessment Report (RAR) which was submitted to the European Food Safety Authority (EFSA) on 3 July 2017 (Spain, [2017](#efs25908-bib-0022){ref-type="ref"}). On 18 October 2017, EFSA initiated a peer review of the pesticides risk assessment on the RMS evaluation, by dispatching the RAR to the Member States and applicants for consultation and comments in line with the provisions of Commission Implementing Regulation (EU) No 844/2012. In addition, a public consultation was also conducted.

After the completion of the commenting period, and following a comment evaluation phase, on 4 July 2018, EFSA requested the applicants to provide certain additional information related to all areas of the assessment including mammalian toxicology in accordance with Article 13(3) of Regulation (EU) No 844/2012, which was evaluated by the RMS and presented in an updated RAR (Spain, [2019a](#efs25908-bib-0023){ref-type="ref"}). Subsequently, in April 2019, a meeting of experts from EFSA and Member States, including relevant experts from the EFSA PPR Panel, took place to discuss certain elements related to mammalian toxicology.

By means of the mandate received on 1 July 2019 from the European Commission, prior to completion of the full peer review process, EFSA was requested to provide a statement with an overview of the available outcomes of the human health assessment in the context of the peer review of chlorpyrifos‐methyl.

Accordingly, on 31 July 2019, EFSA delivered a statement outlining the main findings of the assessment related to mammalian toxicology and human health following the pesticides peer review expert discussions in mammalian toxicology held in April 2019, including EFSA\'s additional considerations and an indication whether the active substance can be expected to meet the approval criteria which are applicable to human health as laid down in Article 4 of Regulation (EC) No 1107/2009[2](#efs25908-note-1006){ref-type="fn"}.

After the Pesticides Peer Review Experts' meeting in April 2019, EFSA reconsidered the read‐across approach applied for the hazard identification of chlorpyrifos‐methyl after a full comparison of the available toxicological data: it was agreed to rediscuss this issue in an additional experts' meeting. EFSA considered that the outcome of the discussions might had an impact on the assessment of the specific studies, on the possibility to consider if criteria for classification may be met, as well as on the setting of reference values for chlorpyrifos‐methyl. EFSA therefore organised an expert meeting which took place on 5 September 2019, in particular to reconsider the read‐across with chlorpyrifos, the genotoxicity potential and the possibility of setting of reference values, taking also into account the comments submitted by the applicants on the previous statement (EFSA, [2019](#efs25908-bib-0005){ref-type="ref"}).

Following rediscussion of the substance, EFSA updated its statement issued on 31 July 2019 to complete the assessment related to human health following the two rounds of expert meetings.

The list of endpoints for the active substance and the representative formulations assessed in the context of the peer review with regard to the impact on human health is available in Appendix [A](#efs25908-sec-1001){ref-type="sec"}.

1.1. Background and Terms of Reference as provided by the requestor {#efs25908-sec-0004}
-------------------------------------------------------------------

On 1 July 2019 EFSA was mandated by the European Commission to provide a statement with an overview on the available outcomes of the human health assessment in the context of the pesticides peer review for the renewal of approval of the active substance chlorpyrifos‐methyl conducted in accordance with Commission Implementing Regulation (EU) No 844/2012.

In addition, EFSA was requested to indicate, whether the active substance chlorpyrifos‐methyl can be expected to meet the approval criteria which are applicable to human health as laid down in Article 4 of Regulation (EC) No 1107/2009.

Accordingly, EFSA delivered a statement to the Commission on 31 July 2019. Following re‐discussion of the substance in the Pesticides Peer Review Experts' meeting on mammalian toxicology held on 5 September 2019, by means of a follow up mandate received on 24 September 2019, EFSA was requested to update the statement issued on 31 July 2019 to take into account the outcome of that expert meeting. EFSA was requested to deliver the updated statement by 31 October 2019 for further consideration during the decision‐making phase.

2. Assessment {#efs25908-sec-0005}
=============

2.1. Mammalian toxicity {#efs25908-sec-0006}
-----------------------

The toxicological profile of the active substance chlorpyrifos‐methyl was discussed at the Pesticides Peer Review Experts' Meetings 01 (April 2019) and 11 (September 2019) and assessed based on the following guidance documents: SANCO/10597/2003‐rev. 10.1 (European Commission, [2012](#efs25908-bib-0009){ref-type="ref"}), Guidance on dermal absorption (EFSA PPR Panel, [2012](#efs25908-bib-0006){ref-type="ref"}), ECHA/EFSA Guidance for the identification of endocrine disruptors (ECHA and EFSA, [2018](#efs25908-bib-0004){ref-type="ref"}) and Guidance on the application of the classification, labelling and packaging (CLP) Criteria (ECHA, [2017](#efs25908-bib-0003){ref-type="ref"}).

The hazard assessment of chlorpyrifos‐methyl discussed in the Pesticides Peer Review Experts' meeting in April 2019 was largely based on the structural similarity with chlorpyrifos. After the experts' meeting, EFSA considered to rediscuss the read‐across approach applied for the hazard identification in a dedicated experts' meeting, which took place in September 2019.

It was recognised that in chlorpyrifos‐methyl, although the chemical structure is similar to chlorpyrifos, the different length of the two alkoxy groups attached to the phosphorus atom (methoxy for chlorpyrifos‐methyl and ethoxy for chlorpyrifos) has uneven consequences on their interaction with serine hydrolases. In addition, differences in the steric orientation of the moiety attached to the enzyme between chlorpyrifos and chlorpyrifos‐methyl could affect the stability of the phosphorylated enzyme leading to variations in the rates of regeneration and ageing of the inhibited AChE (acetylcholinesterase). Differences in the rates of reactivation or ageing due to the structural differences could contribute to the toxicity differences of the two compounds.

Besides, both compounds have different acute toxicity (LD~50~ chlorpyrifos‐methyl \> LD~50~ chlorpyrifos), slightly different potency upon short‐term exposure (being chlorpyrifos‐methyl ten times less potent than chlorpyrifos in rats and dogs), but the same level of toxicity upon long‐term exposure likely due to cumulative AChE inhibition over time. In addition to inhibition of the nervous system and RBC AChE, observed after administration of both chlorpyrifos and chlorpyrifos‐methyl, chlorpyrifos‐methyl presented additional critical effects in short‐term and long‐term toxicity studies on the adrenals.

Regarding the technical specifications of the substance placed on the market by either of the two applicants, they are not supported by the toxicological assessment since most impurities were not tested at the levels in the technical specification. However, regarding the toxicological relevance of the impurities, considering the toxicological profile of chlorpyrifos‐methyl, as discussed in the April 2019 peer review meeting, it is not expected that the impurities present in the technical specification would have the potential to add additional hazard established for the parent. Two impurities (sulfotemp and sulfotemp ester) have been considered as toxicologically relevant by the European Commission (European Commission, [2012](#efs25908-bib-0009){ref-type="ref"}) who established a maximum level of 5 g/kg. Therefore, their maximum levels in the newly proposed technical specification of 5 and 3 g/kg, respectively, are in agreement with these requirements. The analytical methods used in the toxicological studies were not available for most of the studies, representing a concern in particular for the genotoxicity assessment (based on regulatory studies) but not for the critical findings which were retrieved for chlorpyrifos from the published literature (such as the Columbia Center for Children\'s Environmental Health (CCCEH) study).

In rats, chlorpyrifos‐methyl is extensively absorbed after oral administration, it is widely distributed, extensively metabolised through de‐methylation, hydrolysis and conjugation, and eliminated mostly through urine within 72 h. An *in vitro* metabolism study indicates that the metabolic profiles in rat and human are qualitatively similar, but different in quantitative terms. Chlorpyrifos‐methyl metabolism rate in humans is lower compared to that of rats *in vitro*.

In the acute toxicity studies, chlorpyrifos‐methyl showed low toxicity when administered by the oral, dermal or inhalation routes. The substance did not elicit a potential for skin or eye irritation, or for phototoxicity, but was shown to be a skin sensitiser. Accordingly, chlorpyrifos‐methyl is classified according to the CLP criteria as Skin Sens 1, H317 'may cause an allergic skin reaction', as established in Annex VI of Regulation (EC) No 1272/2008[3](#efs25908-note-1007){ref-type="fn"} regarding human health.

At the April 2019 Peer Review Experts' meeting, the experts considered[4](#efs25908-note-1008){ref-type="fn"} that criteria for classification of chlorpyrifos‐methyl as acute neurotoxicant STOT SE 1, in accordance with the criteria set out in Regulation (EC) No 1272/2008, may be met, based on the available toxicological data set.

The main effect following short‐ to long‐term repeated oral administration of chlorpyrifos‐methyl was the inhibition of acetylcholinesterase (AChE) activity, which, at high‐dose levels, was leading to endogenous cholinergic overstimulation resulting in typical cholinergic symptoms. Erythrocyte (red blood cell (RBC)) AChE inhibition was the critical effect in all studies conducted with rats, mice and dogs. Additionally, the adrenals (increased weight, hypertrophy and vacuolation of cells of the zona fasciculata) were identified as target organ of chlorpyrifos‐methyl in rats. The relevant no observed adverse effect level (NOAEL) for short‐term toxicity was 0.65 mg/kg body weight (bw) per day from the 28‐day toxicity study in mice and 0.1 mg/kg bw per day for long‐term exposure from the 2‐year study in rats based on significant decrease of RBC AChE activity in both studies and adrenal toxicity upon long‐term exposure in rats only. No evidence for a carcinogenicity potential was found upon chlorpyrifos‐methyl administration in rats or mice.

No information has been provided on the immunotoxic potential of chlorpyrifos‐methyl, therefore a data gap was identified.

2.2. Genotoxicity {#efs25908-sec-0007}
-----------------

During the Pesticides Peer Review 01 Experts' meeting in April 2019, the experts discussed the *in vitro* and *in vivo* regulatory studies provided in the RAR: gene mutation: the experts considered that the results from the three bacterial and the two mammalian gene mutations assays overall showed that chlorpyrifos‐methyl does not induce gene mutations *in vitro*.chromosome aberration *in vitro*: the results of two different assays were discussed and chlorpyrifos‐methyl was considered positive in the presence of rat liver metabolic activation system (S9) in Chinese hamster ovary (CHO) cells but negative in rat lymphocytes both in the absence and in the presence of S9.unscheduled DNA synthesis (UDS): one *in vitro* study was submitted and produced negative results.*in vivo* studies in somatic cells (mouse bone marrow micronucleus test): the two studies available in the dossier and evaluated in the RAR showed negative findings.*in vivo* rat liver DNA repair test (UDS): chlorpyrifos‐methyl did not damage DNA in rat liver.

The regulatory data package showed positive findings just in one *in vitro* chromosome aberration study in CHO cells in the presence of S9. Overall, the data package did not show any concern and the experts discussed whether DNA damage was sufficiently covered by the available studies. It was also noted that there is no public literature available for chlorpyrifos‐methyl with regard to the genotoxic potential, while several publications were available for chlorpyrifos instead. The experts discussed the structural similarity between chlorpyrifos and chlorpyrifos‐methyl and the similar toxicokinetics of the two molecules and agreed to read across between chlorpyrifos and chlorpyrifos‐methyl. Since concerns were raised for chlorpyrifos with regard to chromosome aberration, DNA damage (oxidative stress and topoisomerase II inhibition), the experts concluded that a data gap is present for chlorpyrifos‐methyl with regard to DNA damage. All the experts agreed that these uncertainties should be considered in the risk assessment of chlorpyrifos‐methyl as well, i.e. it cannot be excluded that chlorpyrifos‐methyl may have DNA damaging potential.

The regulatory database submitted for chlorpyrifos‐methyl did not show any specific concern; very limited literature data on chlorpyrifos‐methyl, including its genotoxicity potential were retrieved. Therefore, the experts concluded that also the genotoxicity potential of chlorpyrifos‐methyl remains unclarified as that of chlorpyrifos. It is noted however that, after the experts' meeting, EFSA reconsidered the read‐across approach applied by the experts and this has been rediscussed in the Pesticides Peer Review Experts' meeting 11 on 5 September 2019. In particular, the experts took into consideration the differences/similarities in chemical structure between the two molecules, their interaction with serine hydrolases and the mammalian toxicological endpoints in acute, short‐ and long‐term studies. Regarding the molecular structure, the experts considered that the differences between chlorpyrifos and chlorpyrifos‐methyl (the presence of the ethyl group instead of the methyl) would not justify a difference in the genotoxicity potential between the two molecules. However, this minor structural difference may contribute to quantitative differences in the acetylcholinesterase (AChE)‐inhibitory effect (and likely other serine‐ hydrolases). In particular, organophosphates (OPs) with a P = O moiety bind covalently to the serine hydrolase residue in the active site of AChE; the phosphorylated enzyme cannot hydrolyse the neurotransmitter acetylcholine. Once phosphorylated, the enzyme may spontaneously reactivate thus regenerating the enzyme (a very slow rate process) or lose one of the two O,O‐dialkyl groups of the phosphate moiety leaving a hydroxyl group in its place and an aged AChE that can no longer be reactivated ('ageing' process). AChE ageing occurs much faster for dimethyl OPs poisoning than for diethyl OPs poisoning.

In addition, the RMS conducted an additional literature search in view of the peer review meeting of September 2019 and found some new public literature studies on chlorpyrifos‐methyl (Pandey et al., [2011](#efs25908-bib-0015){ref-type="ref"}; Singh et al., [2012](#efs25908-bib-0021){ref-type="ref"}; Zhou et al., [2012](#efs25908-bib-0027){ref-type="ref"}; Shin et al., [2014](#efs25908-bib-0018){ref-type="ref"}, [2015](#efs25908-bib-0019){ref-type="ref"}; Hayat et al., [2019](#efs25908-bib-0011){ref-type="ref"}; Yang et al., [2019](#efs25908-bib-0026){ref-type="ref"}) providing some evidence along the same line as those considered for chlorpyrifos. All experts agreed that the genotoxicity data package in regulatory studies for chlorpyrifos‐methyl is complete and overall negative. However, the majority of experts considered that the public literature indications, although presenting some limitations (e.g. literature search methodology, no guideline compliant studies, no data reported for positive controls, etc.), should be considered in a weight‐of‐evidence approach and raised concerns over the potential for DNA damage for chlorpyrifos‐methyl, by adopting a conservative approach.

EFSA notes that US EPA concluded that chlorpyrifos‐methyl is likely less toxic than chlorpyrifos‐ethyl based on a side‐by‐side comparison of cholinesterase inhibition levels in existing studies. US EPA has also concluded that given the structural similarities between the two chemicals, toxicity data using chlorpyrifos‐ethyl could be used to address data gaps for chlorpyrifos‐methyl (<https://www.govinfo.gov/content/pkg/FR-2004-07-07/pdf/04-15209.pdf>).

The previous conclusions regarding a concern for genotoxicity of chlorpyrifos‐methyl raised during the April 2019 expert\'s meeting were therefore confirmed by the majority of experts, and the genotoxic potential of chlorpyrifos‐methyl is considered inconclusive. No reference values could be set.

2.3. Reproductive/developmental toxicity and endocrine disruption {#efs25908-sec-0008}
-----------------------------------------------------------------

In a two‐generation reproductive toxicity study in rats, chlorpyrifos‐methyl did not affect the reproductive performance up to the highest dose of 10 mg/kg bw per day tested, while RBC AChE inhibition and adrenal toxicity were the critical effects related to parental toxicity with a NOAEL of 1 mg/kg bw per day; in this study, RBC AChE inhibition was the critical effect in pups with a NOAEL of 3 mg/kg bw per day. Developmental toxicity was investigated in rats and rabbits. Erythrocyte AChE and brain AChE inhibition were the critical effects identified regarding maternal toxicity in rats, while no adverse effect was observed in rabbits. No developmental adverse effects were observed in either rats or rabbits.

The availability of a multigenerational study conducted according to the most recent test guideline showed no evidence for endocrine‐mediated adversity for the androgen, oestrogen and steroidogenesis pathways at dose levels not producing signs of overt toxicity (AChE inhibition). The same conclusion was reached for the thyroid endocrine‐mediated pathway. On this basis, it was concluded that mechanistic studies are not required to assess the endocrine disruption potential of chlorpyrifos‐methyl following the guidance for identification of endocrine disruptors (ECHA and EFSA, [2018](#efs25908-bib-0004){ref-type="ref"}). On this basis, all experts agreed that chlorpyrifos‐methyl is not an endocrine disruptor in humans.

2.4. Developmental neurotoxicity (DNT) {#efs25908-sec-0009}
--------------------------------------

During the Pesticides Peer Review 01 Experts' meeting in April 2019, Member State experts and two experts from EFSA\'s Panel on Plant Protection Products and their Residues (PPR Panel), discussed the available data regarding developmental neurotoxicity (DNT) of chlorpyrifos‐methyl. They took into consideration and discussed in detail: (a) the DNT study in rats from 2015 (Spain, [2019a](#efs25908-bib-0023){ref-type="ref"}); (b) public literature presented in the systematic review provided by the applicants; (c) additional literature provided by the experts or during the commenting period.

In the DNT study in rats, pregnant rats were exposed to different levels of chlorpyrifos‐methyl (0, 2, 10 and 50 mg/kg bw per day) from day 6 of gestation until lactation day 21. The only effects observed were test substance‐related and statistically significant lower RBC AChE and brain AChE activity values compared to the control group in maternal generation at 10 and 50 mg/kg bw per day. Regarding offspring toxicity, pup growth, survival and clinical conditions were unaffected; according to the RMS, no test substance‐related effects were observed on body weights, body weight gains, attainment of developmental landmarks, detailed clinical observations, motor activity, auditory startle, learning and memory, macroscopic examinations and measurements, neuropathology or brain morphometry at any dietary concentration at any age. However, it should be noted that a significant decrease in the height of cerebral hemisphere on post‐natal day (PND) 72 was observed in males at the top dose. In addition, a statistically significant inhibition of RBC AChE was observed in males at 50 mg/kg bw per day on PND 21. At the experts' meeting in April 2019, all the experts agreed to set a maternal NOAEL at 2 mg/kg bw per day based on decreased RBC AChE and brain AChE activity. The experts noted that, despite the study was performed according to current OECD 426 guideline (OECD, [2007](#efs25908-bib-0014){ref-type="ref"}), the cerebellum height in pups (considered the most sensitive endpoint in the DNT study performed with chlorpyrifos) could not be evaluated since just three control samples in females were available on PND 72. Therefore, considering the low statistical power, no reliable analysis could be performed, representing a major deviation from the study protocol. No changes in cerebellum height were reported for males and females at PND 21 and for males at PND 72, but the measurement was only available at the highest dose. In addition, it should be noted that cerebellum height was not corrected by brain weight and reanalysis of the data corrected for brain weight would be useful to compare also the results presented by Mie et al. ([2018](#efs25908-bib-0013){ref-type="ref"}) in the case of chlorpyrifos, although recognising that statistical analysis could not be performed in the absence of sufficient control samples in females.

All the experts, but one, agreed that, the DNT study on chlorpyrifos‐methyl being inconclusive, a DNT NOAEL could not be set and the LOAEL of 0.3 mg/kg bw per day derived from the data on chlorpyrifos (study from 1998; Spain [2019b](#efs25908-bib-0024){ref-type="ref"}) could be conservatively applied to chlorpyrifos‐methyl. During the Pesticides Peer Review Experts' meeting in September 2019, the experts confirmed that the genotoxic potential of chlorpyrifos‐methyl is inconclusive and therefore no toxicological reference values could be set. Therefore, the developmental neurotoxicity potential of chlorpyrifos‐methyl was not further discussed. However, as already pointed out during the experts' meeting in April 2019, the RMS reiterated that several parameters related to cerebellum were not reported in the DNT study due to the insufficient number of data. In more detail, the RMS presented the raw data on cerebellum height in the controls and high dose treated pups on both PND 21 and 72: it was noted that on PND 21, the number of samples available in both the controls and high dose treated males was quite low (n = 4 and 2, respectively, instead of 10 samples, as foreseen) and in females, it was limited (n = 7 and 5, respectively); on PND 72, the number of samples available for control and high dose treated males was quite high (n = 9 and 9, respectively), while insufficient in females (n = 1 -- not 3 as erroneously indicated in the experts' meeting in April 2019 -- and 3, respectively). The applicant Ascenza Agro S.A. acknowledged that there were insufficient data to evaluate the height of cerebellum on PND 72 control females and proposed to combine males and females together (to have 10 control animals and 12 high dose animals in total); however, although useful, it was noted that this approach represents a deviation from the protocol. By combining the data, no effect on cerebellum height was shown; in addition, Ascenza Agro S.A. considered that the data of cerebellum height corrected by brain weight were not necessary since brain weight data were not significantly different. The RMS also indicated that the data on measurement of the base of the lobule 9 of cerebellum on PND 72 in females were missing for all control samples and in 9 out of 10 samples. The experts agreed that particularly the insufficient number of data related to cerebellum height should be regarded as an important deficiency, since the measurement of cerebellum height was considered a critical parameter to assess developmental neurotoxicity for chlorpyrifos.

Furthermore, according to the RMS, the relevance of the significant difference observed in the height of cerebral hemisphere in 50 mg/kg bw per day treated males at PND 72 when compared to control males cannot be discarded just because no other signs had been observed. Especially considering that the indications from the initial experimental design specified that the correct follow‐up after this observation should had been to measure the same parameter in the low and intermediate dose treated animals. However, this was not applied in this case. Therefore, these deficiencies lead the RMS to consider this study acceptable with reservations.

The experts discussed the epidemiological evidence showing associations between chlorpyrifos and chlorpyrifos‐methyl exposure during neurodevelopment and adverse health effects (attention deficit/hyperactivity disorders, decrease in intelligent quotient and working memory, etc.). In particular, three main birth cohort studies were considered: the Columbia Center for Children\'s Environmental Health (CCCEH) study (US EPA, [2016](#efs25908-bib-0025){ref-type="ref"}), the Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) (Castorina et al., [2010](#efs25908-bib-0001){ref-type="ref"}; Marks et al., [2010](#efs25908-bib-0012){ref-type="ref"}) and Mt. Sinai study (Sebe et al., [2005](#efs25908-bib-0017){ref-type="ref"}). Using different biomarkers of exposure, these studies show that prenatal exposure to organophosphates (OPs) produces a consistent pattern of early cognitive and behavioural deficits (Rauh et al., [2012](#efs25908-bib-0016){ref-type="ref"}). The experts discussed also other epidemiological evidence from the public literature. The majority of the experts considered that the results from some of these studies (mainly from CCCEH study, Rauh et al., [2012](#efs25908-bib-0016){ref-type="ref"}; Engel et al., [2011](#efs25908-bib-0007){ref-type="ref"}; Silver et al., [2017](#efs25908-bib-0020){ref-type="ref"}) contribute to the evidence of DNT effects in humans due to the exposure to chlorpyrifos and chlorpyrifos‐methyl and occurring at doses lower than that causing 20% inhibition of AChE. Therefore, this would represent a concern to be taken into consideration for the risk assessment. In addition, it should be noted that in the CHAMACOS study measurement of trichloro‐pyridinol (TCP) in urine,[5](#efs25908-note-1009){ref-type="fn"} common metabolite of both chlorpyrifos and chlorpyrifos‐methyl contributed to the evidence of DNT effects in humans due to the exposure to chlorpyrifos and/or chlorpyrifos‐methyl. The applicant Ascenza Agro S.A. indicated that no epidemiological studies are available for chlorpyrifos‐methyl; however, as indicated above, the measurement of TCP in urine cannot discriminate between the selective exposure to chlorpyrifos or chlorpyrifos‐methyl.

Taking into consideration the DNT study outcome (reduction in cerebellum height for chlorpyrifos -- that could not be explained by the maternal AChE inhibition), the epidemiological evidence showing an association between chlorpyrifos/chlorpyrifos‐methyl exposure during development and neurodevelopmental outcomes, and the overall analysis of the published literature (*in vivo*,*in vitro* and human data), the experts indicated that chlorpyrifos‐methyl, based on the available toxicological data set, may be expected to meet the criteria for classification[4](#efs25908-note-1008){ref-type="fn"} as toxic for the reproduction, REPRO 1B, H360D 'May damage the unborn child' in accordance with the criteria set out in Regulation (EC) No 1272/2008. EFSA expresses some reservations on this approach, as based on the current experience the criteria for classification would normally be based on the specific effects recorded in good quality data. However, the European Chemicals Agency (ECHA) will be responsible for the final decision.

3. Conclusions {#efs25908-sec-0010}
==============

During the Pesticides Peer Review 01 Experts' meeting in April 2019, all the experts, but one, agreed that the Point of Departure (PoD) for setting the reference values for chlorpyrifos‐methyl, in the absence of data on cerebellum height corrected by brain weight in the DNT study with chlorpyrifos‐methyl (2015; Spain, [2019a](#efs25908-bib-0023){ref-type="ref"}), should be, as a conservative assumption, the DNT LOAEL of 0.3 mg/kg bw per day from the DNT study on chlorpyrifos (1988; Spain, [2019b](#efs25908-bib-0024){ref-type="ref"}), based on the severity of the effects, until there is no evidence for the contrary. The subject has been rediscussed in the Pesticides Peer Review Experts' meeting in September 2019.

In the peer review meeting in April 2019, the experts concluded that: the concerns raised for chlorpyrifos with regard to chromosome aberration and DNA damage (oxidative stress and topoisomerase II inhibition) may apply to chlorpyrifos‐methyl, resulting in an unclear genotoxicity potential;the DNT effects observed at the lowest dose tested in the DNT study with chlorpyrifos (decrease in cerebellum height corrected by brain weight), indicating a health concern, would be conservatively applied to chlorpyrifos‐methyl;the epidemiological evidence supports the developmental neurological outcomes in children for both chlorpyrifos and chlorpyrifos‐methyl.

Overall, considering the unclear genotoxicity effects reported with chlorpyrifos and the bridging with chlorpyrifos‐methyl, the experts agreed that no toxicological reference values could be established for chlorpyrifos‐methyl. Furthermore, additional significant uncertainties were linked to the concerns identified in the DNT study with chlorpyrifos, which was considered applicable to chlorpyrifos‐methyl, supported by the available epidemiological evidence related to developmental neurological outcomes in children. Due to the lack of toxicological reference values, a risk assessment for consumers, operators, workers, bystanders and residents cannot be conducted. This issue represents a critical area of concern for chlorpyrifos‐methyl.

Based on the above and also considering the recorded toxicological effects meeting the criteria for classification as toxic for reproduction category 1B (regarding developmental toxicity), it is considered that the approval criteria which are applicable to human health as laid down in Article 4 of Regulation (EC) No 1107/2009, are not met. EFSA expresses some reservations on this approach since such a conservative approach may not apply to classification and labelling.

The hazard assessment of chlorpyrifos‐methyl discussed in the Pesticides Peer Review Experts' meeting in April 2019 was largely based on the structural similarity with chlorpyrifos. It is noted that, after the experts' meeting, EFSA reconsidered the read‐across approach applied for the hazard identification after a full comparison of the available toxicological data: it was agreed to rediscuss this issue in an additional experts' meeting. EFSA therefore organised an expert meeting which took place on 5 September 2019, in particular to reconsider the read across with chlorpyrifos, the genotoxicity potential and the possibility of setting of reference values, taking also into account the comments submitted by the applicants on the previous statement (EFSA, [2019](#efs25908-bib-0005){ref-type="ref"}).

Since Member State experts confirmed that the genotoxic potential of chlorpyrifos‐methyl is inconclusive, it was also confirmed that no toxicological reference values could be set.

Glossary and abbreviations {#efs25908-sec-0011}
==========================

AAOELacute acceptable operator exposure levelAChEacetylcholinesteraseADIacceptable daily intakeAOELacceptable operator exposure levelARfDacute reference doseAUCarea under the blood concentration/time curvebwbody weightCCCEHColumbia Center for Children\'s Environmental HealthCHAMACOSCenter for the Health Assessment of Mothers and Children of SalinasCHOChinese hamster ovaryCLPclassification, labelling and packagingCmaxconcentration achieved at peak blood levelCNScentral nervous systemco‐RMSco‐rapporteur Member StateDNTdevelopmental neurotoxicityEATSoestrogen, androgen, thyroid, steroidogenesisECHAEuropean Chemicals AgencyHGPRThypoxanthine‐guanine phosphoribosyl transferaseLC50lethal concentration, medianLD50lethal dose, median; dosis letalis mediaLOAELlowest observable adverse effect levelNOAELno observed adverse effect levelOECDOrganisation for Economic Co‐operation and DevelopmentOPorganophosphatePNDpost‐natal dayPoDpoint of departureppbparts‐per‐billion (10^9^)PPR panelEFSA\'s Panel on Plant Protection Products and their ResiduesQSARquantitative structure--activity relationshipRARRenewal Assessment ReportRBCred blood cellsRMSrapporteur Member StateS9rat liver metabolic activation systemt1/2half‐life (define method of estimation)UDSunscheduled DNA synthesisUS EPAUnited States Environmental Protection Agency

Appendix A -- List of end points for the active substance and the representative formulations with regard to impact on human health {#efs25908-sec-1001}
===================================================================================================================================

1. Impact on human and animal health {#efs25908-sec-0012}
------------------------------------

**Absorption, distribution, metabolism and excretion (toxicokinetics) (Regulation (EU) No 283/2013, Annex Part A, point 5.1)**

![](EFS2-17-e05908-g001.jpg "image")

**Acute toxicity (Regulation (EU) No 283/2013, Annex Part A, point 5.2)**

![](EFS2-17-e05908-g002.jpg "image")

**Short‐term toxicity (Regulation (EU) No 283/2013, Annex Part A, point 5.3)**

![](EFS2-17-e05908-g003.jpg "image")

**Genotoxicity (Regulation (EU) No 283/2013, Annex Part A, point 5.4)**

![](EFS2-17-e05908-g004.jpg "image")

**Long‐term toxicity and carcinogenicity (Regulation (EU) No 283/2013, Annex Part A, point 5.5)**

![](EFS2-17-e05908-g005.jpg "image")

**Reproductive toxicity (Regulation (EU) No 283/2013, Annex Part A, point 5.6) Reproduction toxicity**

![](EFS2-17-e05908-g006.jpg "image")

**Developmental toxicity**

![](EFS2-17-e05908-g007.jpg "image")

**Neurotoxicity (Regulation (EU) No 283/2013, Annex Part A, point 5.7)**

![](EFS2-17-e05908-g008.jpg "image")

**Other toxicological studies (Regulation (EU) No 283/2013, Annex Part A, point 5.8)**

![](EFS2-17-e05908-g009.jpg "image") ![](EFS2-17-e05908-g010.jpg "image")

**Medical data (Regulation (EU) No 283/2013, Annex Part A, point 5.9)**

![](EFS2-17-e05908-g011.jpg "image")

**Summary** [**6**](#efs25908-note-1010){ref-type="fn"} **(Regulation (EU) N°1107/2009, Annex II, point 3.1 and 3.6)**

![](EFS2-17-e05908-g012.jpg "image")

**Dermal absorption (Regulation (EU) No 284/2013, Annex Part A, point 7.3)**

![](EFS2-17-e05908-g013.jpg "image")

**Exposure scenarios (Regulation (EU) N° 284/2013, Annex Part A, point 7.2)**

![](EFS2-17-e05908-g014.jpg "image")

**Classification with regard to toxicological data (Regulation (EU) N° 283/2013, Annex Part A, Section 10)**

![](EFS2-17-e05908-g015.jpg "image")

Appendix B -- Used compound codes {#efs25908-sec-1002}
=================================

 {#efs25908-sec-0013}

Code/trivial nameIUPAC name/SMILES notation/InChIKey[(a)](#efs25908-note-1012){ref-type="fn"}Structural formula[(b)](#efs25908-note-1013){ref-type="fn"}chlorpyrifos*O,O‐*diethyl *O*‐3,5,6‐trichloro‐2‐pyridyl phosphorothioate Clc1cc(Cl)c(Cl)nc1OP(=S)(OCC)OCC SBPBAQFWLVIOKP‐UHFFFAOYSA‐N![](EFS2-17-e05908-g016.jpg "image")chlorpyrifos‐methyl*O,O*‐dimethyl *O*‐3,5,6‐trichloro‐2‐pyridyl phosphorothioate Clc1cc(Cl)c(Cl)nc1OP(=S)(OC)OC HRBKVYFZANMGRE‐UHFFFAOYSA‐N![](EFS2-17-e05908-g017.jpg "image")des‐methyl chlorpyrifos‐methyl (DEM)*O*‐methyl *O*‐(3,5,6‐trichloro‐2‐pyridyl) hydrogen phosphorothioate Clc1cc(Cl)c(Cl)nc1OP(O)(=S)OC DYESOQMZDNCQNZ‐UHFFFAOYSA‐N![](EFS2-17-e05908-g018.jpg "image")sulfotemp*O,O,O′,O′‐*tetramethyl dithiopyrophosphate COP(=S)(OC)OP(=S)(OC)OC XKBNJDRCYDBEAH‐UHFFFAOYSA‐N![](EFS2-17-e05908-g019.jpg "image")sulfotemp ester*O,O,O′‐*trimethyl *O′‐(*3,4,6‐trichloro‐2‐pyridyl) dithiopyrophosphate Clc1c(OP(=S)(OC)OP(=S)(OC)OC)nc(Cl)cc1Cl WDHGBTACZJLMHA‐UHFFFAOYSA‐N![](EFS2-17-e05908-g020.jpg "image")TCP3,5,6‐trichloro‐2‐pyridinol Clc1cc(Cl)c(Cl)nc1O WCYYAQFQZQEUEN‐UHFFFAOYSA‐N![](EFS2-17-e05908-g021.jpg "image")TMP2,3,5‐trichloro‐6‐methoxypyridine Clc1cc(Cl)c(Cl)nc1OC RLIVUWLXZBDMBL‐UHFFFAOYSA‐N![](EFS2-17-e05908-g022.jpg "image")3,6‐DCP3,6‐dichloro‐2‐pyridinol Oc1nc(Cl)ccc1Cl UGPDKBDRRLFGFD‐UHFFFAOYSA‐N![](EFS2-17-e05908-g023.jpg "image")[^1][^2]

Commission Implementing Regulation (EU) No 844/2012 of 18 September 2012 setting out the provisions necessary for the implementation of the renewal procedure for active substances, as provided for in Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market. OJ L 252, 19.9.2012, p. 26.

Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. OJ L 309, 24.11.2009, p. 1.

Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006. OJ L 353, 31.12.2008, p. 1--1355.

It should be noted that classification is formally proposed and decided in accordance with Regulation (EC) No 1272/2008.

Post‐meeting note: it is also possible that a significant portion of TCP present in urine samples can result from direct intake of TCP preformed in the environment and not as a result of chlorpyrifos or chlorpyrifos‐methyl ingestion (Eaton et al., [2008](#efs25908-bib-0002){ref-type="ref"}).

for metabolites, refer to section: Studies performed on metabolites or impurities.

Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006. OJ L 353, 31.12.2008, 1--1355.

[^1]: ACD/Name 2018.2.2 ACD/Labs 2018 Release (File version N50E41, Build 103230, 21 Jul 2018).

[^2]: ACD/ChemSketch 2018.2.2 ACD/Labs 2018 Release (File version C60H41, Build 106041, 07 Dec 2018).
